MSF calls for price cuts on another TB drug, J&J's bedaquiline

10 October 2019

Médecins Sans Frontières/Doctors Without Borders (MSF) is today calling on pharmaceutical company Johnson & Johnson (NYSE: JNJ) to lower the price of its anti-tuberculosis medicine bedaquiline to no more than $1 per day for those who need it.

Adding to the similar MSF call regarding Mylan’s (Nasdaq: MYL) TB drug Deltyba (delamanid) just a couple of days earlier, this would allow greater access to drug-resistant TB (DR-TB) treatment and reduce deaths. MSF demands this price cut considering the joint contributions made in the development of this drug, including by MSF itself.

“Those who contributed to bedaquiline’s development should have a say in how the drug is priced. We’re calling on J&J to price bedaquiline at no more than $1 per day so that it can be made available to all people with drug-resistant TB. We will not back down until the price of bedaquiline is brought down,” said Sharonann Lynch, HIV & TB Policy Advisor for MSF’s Access Campaign.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK